NCOAT (Nucleolar Complex Associated Transporter), also known as MGEA5 (meningioma expressed antigen 5), is an O-GlcNAcase enzyme that plays a critical role in the dynamic post-translational modification of nuclear and cytosolic proteins by removing O-linked N-acetylglucosamine (O-GlcNAc). This modification is pivotal for regulating various cellular processes, including signal transduction, transcription, and protein degradation. NCOAT's function is essential in the balance of O-GlcNAcylation, a process that competes with phosphorylation on serine and threonine residues of proteins, thereby influencing cellular signaling pathways, the cell cycle, and stress responses. The enzyme's activity affects numerous proteins involved in critical cellular functions, highlighting its importance in maintaining cellular homeostasis and its potential role in the pathogenesis of diseases such as diabetes, neurodegenerative disorders, and cancer, where aberrant O-GlcNAcylation is often observed.
The activation of NCOAT is intricately regulated by various mechanisms that ensure its proper function in response to cellular needs. One primary mode of activation involves changes in the cellular concentration of UDP-GlcNAc, the substrate for O-GlcNAc transferase (OGT), which is responsible for adding O-GlcNAc to proteins. An increase in UDP-GlcNAc levels can indirectly signal a greater need for NCOAT activity to remove excess O-GlcNAc, maintaining the balance of O-GlcNAcylation. Additionally, NCOAT itself can be subject to post-translational modifications, including phosphorylation, which may alter its enzyme activity or specificity. Regulatory proteins may also interact with NCOAT, modulating its activity or localization within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
A potent PKC inhibitor that indirectly activates NCOAT. It inhibits PKC, reducing its negative modulation on NCOAT, thus promoting NCOAT activation through the suppression of PKC-mediated inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR inhibitor that indirectly activates NCOAT. By blocking EGFR signaling, Gefitinib disrupts downstream pathways negatively regulating NCOAT, allowing for increased activation of NCOAT through relief from inhibitory signals. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
A GSK-3 inhibitor that directly activates NCOAT. By inhibiting GSK-3, SB216763 prevents the phosphorylation of NCOAT by GSK-3, leading to increased NCOAT activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
An adenylate cyclase activator that indirectly activates NCOAT. Forskolin increases cAMP levels, which activate PKA. Activated PKA, in turn, phosphorylates and activates NCOAT, resulting in enhanced NCOAT activity. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
A protein phosphatase inhibitor that directly activates NCOAT. Calyculin A inhibits protein phosphatases, preventing the dephosphorylation of NCOAT and maintaining its active phosphorylated state. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
A PKC inhibitor that indirectly activates NCOAT. Similar to Bisindolylmaleimide I, Ro 31-8220 inhibits PKC, releasing the negative modulation on NCOAT and promoting its activation through the suppression of PKC-mediated inhibition. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
An EGFR inhibitor that indirectly activates NCOAT. AG1478 disrupts EGFR signaling, alleviating the downstream negative modulation of NCOAT by EGFR. This leads to increased NCOAT activation through the removal of inhibitory signals from EGFR. | ||||||